Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer

The combination of GM-CSF + thalidomide is relatively well tolerated and has the potential to produce antitumor activity in a population of patients with metastatic, androgen independent prostate cancer. This nonchemotherapy combination should be explored in a subset of patients with less advanced disease.